Antibody-drug conjugates (ADCs) have emerged as a rapidly evolving, highly promising class of oncology drugs, with 12 approvals and many more in development. Despite their success, the therapeutic window remains relatively narrow, posing challenges for finding an optimal dose.

In the face of evolving regulatory guidance and more complex ADCs entering development, the inaugural ADC Pharmacokinetics and Clinical Pharmacology Summit comes to life this October to provide in-depth pharmacokinetic and clinical pharmacology insights to help ADC developers select a clinical dose that maximizes efficacy whilst limiting toxicities and drive more ADCs to BLA approval quicker.

As the next generation of ADCs becomes even more complex, this further emphasizes the need for a clear strategy for those working within PK/PD, bioanalysis, pharmacometrics and clinical pharmacology to support the tricky translation from non-clinical studies into clinical trials.

See how others are approaching the early establishment of a clear mechanistic link between ADC design and PK profile, utilizing pharmacometrics and PK/PD data to inform dose optimization for FIH, later phase dosage and ADC combination therapies.

Category: Conferences | Science, Health and Medicine

Date and Time: 8th October 2024 at 8:00 am to 10th October 2024 at 5:00 pm

Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States